Frontiers in oncology · 2026
Characteristics and influencing factors of sleep disturbance in breast cancer patients: a cross-sectional study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Yi, Wang Yan, Fang Yuhang, Zhu Guanghui, Sui Bailu, Yuan Xinhe, Chen Yu, Li Mengyang, Fan Wei, Zhang Ying
Аннотация
BACKGROUND: With prolonged survival of breast cancer patients, symptom management is increasingly pivotal. Sleep disturbance, a prevalent and persistent quality-of-life-impairing symptom, remains incompletely elucidated, thus this study aims to clarify its clinical characteristics and influencing factors.
METHODS: A total of 150 breast cancer patients were recruited. Sleep disturbance was assessed using the Pittsburgh Sleep Quality Index (PSQI). Pain was evaluated with the Visual Analogue Scale (VAS), fatigue via the Revised Piper Fatigue Scale (PFS-R), and emotional status through the Hospital Anxiety and Depression Scale (HADS). Multivariate logistic regression was conducted to ascertain associated factors.
RESULTS: Approximately 68.67% of patients exhibited "moderate" or "severe" sleep disturbance (PSQI score >10), with difficulty falling asleep as the predominant type of sleep disturbance. Univariate analysis showed that receipt of ovarian function suppression (OFS) and/or aromatase inhibitor (AI) therapy, pain, fatigue, anxiety, and depression were associated with exacerbated sleep disturbance, while multivariate analysis revealed that each 1-point increase in pain, fatigue, and depression scores was independently associated with a 23.7%, 25.0%, and 23.7% higher risk of severe sleep disturbance, respectively.
CONCLUSION: Sleep disturbance is highly prevalent and severe in breast cancer patients, with difficulty falling asleep as the core feature. Clinical practice should focus on patients with the aforementioned influencing factors, prioritizing interventions targeting shortened sleep latency.
METHODS: A total of 150 breast cancer patients were recruited. Sleep disturbance was assessed using the Pittsburgh Sleep Quality Index (PSQI). Pain was evaluated with the Visual Analogue Scale (VAS), fatigue via the Revised Piper Fatigue Scale (PFS-R), and emotional status through the Hospital Anxiety and Depression Scale (HADS). Multivariate logistic regression was conducted to ascertain associated factors.
RESULTS: Approximately 68.67% of patients exhibited "moderate" or "severe" sleep disturbance (PSQI score >10), with difficulty falling asleep as the predominant type of sleep disturbance. Univariate analysis showed that receipt of ovarian function suppression (OFS) and/or aromatase inhibitor (AI) therapy, pain, fatigue, anxiety, and depression were associated with exacerbated sleep disturbance, while multivariate analysis revealed that each 1-point increase in pain, fatigue, and depression scores was independently associated with a 23.7%, 25.0%, and 23.7% higher risk of severe sleep disturbance, respectively.
CONCLUSION: Sleep disturbance is highly prevalent and severe in breast cancer patients, with difficulty falling asleep as the core feature. Clinical practice should focus on patients with the aforementioned influencing factors, prioritizing interventions targeting shortened sleep latency.